Drug Interaction Study of Olmesartan in Healthy Chinese Volunteers

• Status: Completed
• Trial end date: 2009-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Hypertension and hyperuricaemia are widespread conditions. There is significant overlap between the two conditions. Serum uric acid (SUA) is currently recognized as a risk factor for cardiovascular disease. Thus, at some point in their therapy, hypertensive patients with hyperuricaemia are likely to require concurrent treatment with anti-hypertensive and hypouricaemic agents. For this reason, it is important to determine whether there are any pharmacokinetic interactions resulting from the concomitant administration of such agents.Olmesartan is an angiotensin II receptor antagonist and effective and well tolerated in the treatment of arterial hypertension. Probenecid is a well-established hypouricaemic agent for the treatment of hyperuricaemia and gout.The goal of this study was to examine the impact of coadministration of probenecid on the pharmacokinetic parameters and tolerability of olmesartan in healthy volunteers.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Central South University
• Treatments: Olmesartan; Olmesartan Medoxomil; Probenecid

Criteria

Inclusion Criteria:

• written informed consent obtained,

• age 18 to 40 years and a body mass index between 19 and 25 kg/m2;

• negative test results for HIV and hepatitis В and C non-smoking status and

• an unremarkable clinical history

Exclusion Criteria:

• has history or evidence of a renal, gastrointestinal, hepatic, or hematologic abnormality or

• any acute or chronic disease, or

• an allergy to any drugs